Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
Ronan RousselPatrice DarmonMatthieu PichelinThomas GoronflotYawa AboulekaLeila Ait BachirIngrid AllixAbdallah Al-SalamehSophie BorotLyse BordierAurélie CarlierNicolas ChevalierChristine Coffin-BoutreuxEmmanuel CossonAnne DorangeOlivier DupuyPierre FontaineBénédicte FremyFlorence GaltierNatacha GermainAnne-Marie GuedjEtienne LargerStéphanie Laugier-RobiolleBruno LaviolleLisa LudwigArnaud MonierNathanaëlle MontanierPhilippe MoulinIsabelle MouraGaëtan PrevostYves ReznikNadia SabbahPierre-Jean SaulnierPierre SerusclatCamille VatierMatthieu WargnySamy HadjadjPierre GourdyBertrand Cariounull nullPublished in: Diabetes, obesity & metabolism (2021)
These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.